Zika virus (ZIKV) was spread to both eastward and westward from Uganda where the virus was identified approximately in 1947 by a group of arbovirus researchers. In 2015, ZIKV reached Americas with major outbreaks in Brazil. Most countries with mosquito transmitted ZIKV infection are located in tropical and subtropical areas, where ZIKV is endemic with other flaviviruses, including JEV, dengue and yellow fever virus. Approximately 40 countries in Central and South Americas and territories in South Pacific Islands and South East Asia show autochthonous ZIKV endemics. American lineage of ZIKV is known significantly to be mutated in susceptibility to host and in pathogenicity from Asian and Asian lineages approximately since 2014. Early and specific identification of ZIKV infection is very important for the effective management of patients. First of all, optimal collection of specimens for the laboratory diagnosis is required for both nucleic acid testing (NAT) and serological tests. Specimens for NAT tests and serological tests should be determined by the available laboratory resources, work-flow in each laboratory and the geographic areas of specimen collected in addition to days after showing symptoms. Testing strategy for specific differentiation among flaviviruses will vary depending on the prevalence of viruses known to be circulating in the area where the patients were exposed. NAT will be employed for the patients presenting with onset of symptoms less than 7 days. Advanced diagnostic technologies should be continuously developed for the increase of specificity and sensitivity of ZIKV diagnosis.
I. INTRODUCTION
Zika virus (ZIKV) was isolated and identified from a rhesus macaque by scientists working on yellow fever in Zika Forest, Uganda in 1947 (1) . Subsequently, the virus was isolated from a human in Africa 5 years later. The monkey virus must have been converted to be virulent virus when the virus changed host to another species of monkey and human (2) . Historically, ZIKV in early period after emergence was rarely associated with diseases in humans (http://www.who.int/emergencies/zika-virus/en/) (3) . ZIKV has continued spreading to eastward and westward throughout the world for more than sixty years without particular attention until 2014 (4, 5) . Nearly 70 years later, the ZIKV found public consciousness because the virus was suspected of association with brain damage in the pregnant women in America including Brazil. 
From early 2016, millions of persons with ZIKV infection
were found with increases of infants with microcephaly in Braool, Brazil (6) . As of mid-2016, ZIKV is spreading to the Americas, the Pacific and Southeast Asia and also affects several islands in the Pacific Islands (5, 7) . Approximately 50 countries or territories worldwide have shown the autochthonous epidemics of ZIKV (4, 8) . ZIKV has obtained public concerns since diseases like microcephaly and GuillainBarre syndrome were increased in several countries in America, mainly in Brazil (9) . Therefore, health authorities worldwide and WHO have had special attentions on the spread of Zika fever.
Naturally it is expected that more persons would be returned to their original countries after their infection in ZIKV epidemic areas, therefore, intensive prevention policies are required to be prepared for those persons infected with ZIKV and general public. Furthermore, increasing neces- In addition to diagnostic reagents, developments of vaccine and therapeutics are required for the better control of the persons related (10) . For the successful development of ZIKV vaccine, understanding on biology, epidemics and other aspects of ZIKV in addition to diagnostic technologies is very important. In this review, advances on ZIKV epidemics and diagnostic technologies are introduced.
II. EMERGENCE AND TRANSMISSION OF ZIKV
2-1 Origins and transmission of ZIKV up to 2014
As described above, ZIKV was accidently discovered from
Macaca mulatta (an old monkey species) in Entebbe, Uganda it is presumed that ZIKV transmitted to mainland America from one of islands with ZIKV epidemics (2, 13) . Also during this outbreak, there must be the evidence of risk that ZIKV could be also transmitted through blood banks, and
ZIKVs were also detected in semen, saliva and urine around 2013 (12, 13).
2-2 Epidemiology of ZIKV worldwide 2014-October 2016
From numerous patients with rash and mild fever and arthralgia, ZIKV infections were first detected in Northeastern Brazil and patient numbers increased during the first months of 2015 (6, 9, 14, 15 
2-3 Prevalence of ZIKV Infection in Korea
No autochthonous infection of ZIKV has been reported so far in Korea. As of 24 September 2016, it was confirmed that 14 persons had been found infected with ZIKV in Korea. So far, no autochthonous ZIKV infected persons were found within Korea (Fig. 3) . The possibility of autochthonous ZIKV epidemics in Korea is assessed to be very low in Korea because of low prevalence of Aedes albopictus species within the country.
Latest person found with ZIKV infection in Korea is

2-4 Control of ZIKV transmission
Most countries throughout the world have followed WHO policies (22) for the effective control of Zika epidemics. Avoiding Aedes species mosquito biting in widespread ZIKV epidemic areas is recommended for the prevention of transmission (14, 24, 25) . The guideline of the CDC and WHO recommends wearing long sleeved clothes in the areas with autochthonous transmission and use of mosquito repellent agents during activity in fields. All the women from the areas of Zika infections who expect to be pregnant should delay pregnancy at least 2 months or longer. Furthermore, partners of women expecting pregnancies should not have sexual activity with their partners for 2 months. In addition, persons infected with ZIKV must avoid sexual contact at least for six months. Neither vaccine nor effective therapeutic drugs are available so far, even though some research reported the efficacy of interferons (16) . In addition, no specific laboratory animal for vaccine or therapeutics except known natural host is presently available (17, 19) . As of November 2016, ZIKV is lifted from quarantine diseases throughout 
III. VIROLOGY OF ZIKV 3-1 Biology of ZIKV
Flaviviruses are enveloped with single stranded positive RNA viruses and ZIKV is inferred to be about 50 nm in diameter, which is compatible with the observations performed for ZIKV (27, 28) . It has been tested that ZIKV was most stable at pH of 6.8~7.4 and inactivated at under pH 6.2 and over pH 7.8. It is known that other flaviviruses, such as JEV, are very sensitive to narrow changes of pH (13) . It might be interesting to investigate the sensitivity range of ZIKV to pH, considering highly narrow pH sensitivity of JEV. ZIKV can also be inactivated by many chemicals, including potassium permanganate, ether, and temperatures of 58℃ for 30 minutes as well (27) . It is well known that the In the screening against anti-ZIKV therapeutics, glutarimide antibiotics, e.g., lactimidomycin, are being tested against various RNA virus including ZIKV and dengue viruses (35) . The antibiotic has shown certain level of anti-ZIKV activities, acting as a direct inhibitor of protein translation in ribosomes, in addition to antimicrobial activities (36) (37) (38) . However, no practical drugs and vaccine against ZIKV are available so far.
3-2 Evolution and classification of ZIKV
ZIKV is classified into the Flavivirus genus within the
Flaviviride family which includes dengue virus, yellow fever virus and JEV (27) . No details on natural host of ZIKV are known so far except natural vertebrate host range, generally including primates as its amplification and reservoir hosts. These adapted genes could facilitate viral replication and increase viral titers, compared with those of other flavivirus, e.g., dengue virus (19) .
Furthermore, it was also disclosed that several ZIKV strains exhibited a 4 amino acids deletion corresponding to the glycosylation motifs in envelope protein 154, found in many flaviviruses. These kinds of mutations could make ZIKV different from other flaviviruses in virulence, transmission and algorithms of laboratory diagnosis (13, 19) .
IV. DETECTION OF PERSONS WITH ZIKV 4-1 Basic concept for viral and antibody test of ZIKV infection
ZIKV is closely related to dengue virus, JEV, and other 
